Are post-merger AbbVie shares 'unsustainably cheap?' One analyst thinks so

12th May 2020 Uncategorised 0

With its megamerger with Allergan finally in the books, AbbVie is officially a colossus with a bustling drug portfolio and a few strategic hurdles in its immediate future. But the new AbbVie will be stronger than ever, one analyst argues—and investors haven’t picked up on that yet. 

More: Are post-merger AbbVie shares 'unsustainably cheap?' One analyst thinks so
Source: fierce